非酒精性脂肪性肝病与肝细胞癌

doi:10.16139/j.1007-9610.2018.03.006

摘要/Abstract

中图分类号:

R735.7

肖永胜, 周俭. 非酒精性脂肪性肝病与肝细胞癌[J]. 外科理论与实践, 2018, 23(03): 210-213.

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志,2010,18(3):163-166.
[2] Bellentani S.The epidemiology of non-alcoholic fatty li-ver disease[J]. Liver Int,2017,37(Suppl 1):81-84.
[3] Fan JG, Farrell GC.Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol,2009,50(1):204-210.
[4] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[5] Rinella ME.Nonalcoholic fatty liver disease: a systematic review[J]. JAMA,2015,313(22):2263-2273.
[6] Powell EE, Cooksley WG, Hanson R, et al.The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years[J]. Hepatology,1990,11(1):74-80.
[7] Marengo A, Rosso C, Bugianesi E.Liver cancer: Connections with obesity, fatty liver, and cirrhosis[J]. Ann Rev Med,2016,67:103-117.
[8] Ertle J, Dechene A, Sowa JP, et al.Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis[J]. Int J Cancer,2010, 128(10):2436-2443.
[9] Dyson J, Jaques B, Chattopadyhay D, et al.Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team[J]. J Hepatol,2014,60(1):110-117.
[10] Younossi ZM, Otgonsuren M, Henry L, et al.Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology,2015,62(6):1723-1730.
[11] Salomao MS, Yu WM, Brown RS, et al.Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH[J]. Am J Surg Pathol,2010,34(11):1630-1636.
[12] Salomao MS, Remotti H, Vaughan R, et al.The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis[J]. Hum Pathol,2012,43(5):737-746.
[13] Shibahara J, Ando S, Sakamoto Y, et al.Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients[J]. Histopathology,2014,64(7):951-962.
[14] Calwell SH, Lee VD, Kleiner DE, et al.NASH and cryptogenic cirrhosis: a histological analysis[J]. Ann Hepatol,2009,8(4):346-352.
[15] Mittal S, Sada Y, El-Serag HB, et al.Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population[J]. Clin Gastroenterol Hepatol,2015,13(3):594-601.
[16] Kikuchi L, Oliveira CP, Alvares-da-Silva MR, et al. Hepa-tocellular carcinoma management in nonalcoholic fatty liver disease patients: applicability of the BCLC staging system[J]. Am J Clin Oncol,2016,39(5):428-432.
[17] Wong RJ, Aguilar M, Cheung R, et al.Nonalcoholic steatohepatitis is the second leading etiology of liver di-sease among adults awaiting liver transplantation in the United States[J]. Gastroenterology,2015,148(3):547-555.
[18] Vigano L, Conci C, Cescon M, et al.Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC[J]. J Hepatol,2015,63(1):93-101.
[19] Reddy SK, Steel JL, Chen HW, et al.Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver di-sease[J]. Hepatology,2012,55(6):1809-1819.
[20] Piscaglia F, Svegliati-Baroni G, Barchetti A, et al.Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study[J].Hepatology,2016,63(3):827-838.
[21] White DL, Kanwal F, El-Serag HB.Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review[J]. Clin Gastroenterol Hepatol,2012,10(12):1342-1359.
[22] Bruix J, Sherman M.Management of hepatocellular carcinoma: an update[J]. Hepatology,2011,53(3):1020-1022.
[23] Singal AG, Yopp AC, Gupta S, et al.Failure rates in the hepatocellular carcinoma surveillance process[J]. Cancer Prev Res,2012,5(9):1124-1130.
[24] Gopal P, Yopp AC, Waljee AK, et al.Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis[J]. Clin Gastroenterol Hepatol,2014,12(5):870-877.
[25] Kawanaka M, Tomiyama Y, Hyogo H, et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease[J]. Hepatol Res,2018-01-07[Epub ahead of print]
[26] Zhang H, Gao C, Fang L, et al.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis[J]. Scand J Gastroenterol,2013,48(1):78-87.
[27] Bhat M, Sonenberg N, Gores GJ.The mTOR pathway in hepatic malignancies[J]. Hepatology,2013,58(2):810-818.
[28] Singh S, Singh PP, Singh AG, et al.Statins are associa-ted with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis[J]. Gastroenterology,2013,144(2):323-332.
[29] Yang B, Yang HP, Ward KK, et al.Bariatric surgery and liver cancer in consortium of academic medical centers[J]. Obes Surg,2016,26(3):696-700.
[30] Torres DM, Williams CD, Harrison SA.Features, diagnosis, and treatment of nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol,2012,10(8):837-858.
[31] Wen CP, Lin J, Yang CY, et al.Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases[J]. J Natl Cancer Inst,2012,104(20):1599-1611.
[32] Piguet AC, Saran U, Simillion C, et al.Regular exercise decreases liver tumors development in hepatocyte-speci-fic PTEN-deficient mice independently of steatosis[J]. J Hepatol,2015,62(6):1296-1303.

非酒精性脂肪性肝病与肝细胞癌

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马婧嶔, 杨敏捷, 颜志平. 精细TACE的治疗目标与栓塞终点[J]. 外科理论与实践, 2022, 27(02): 131-133.
[2]	孙惠川. 肝细胞癌转化治疗的现状与展望[J]. 外科理论与实践, 2022, 27(02): 134-138.
[3]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[4]	管涛(综述), 张倜, 王鲁(审校). 肝细胞癌肺转移的潜在机制和治疗进展[J]. 外科理论与实践, 2022, 27(02): 180-184.
[5]	黄纪伟, 邱国腾, 曾勇. 肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118.
[6]	冯浩, 吕子成, 夏强. 肝癌肝移植全过程管理及治疗进展[J]. 外科理论与实践, 2022, 27(02): 119-122.
[7]	周香雪, 黄海威. 肝豆状核变性影像学研究进展[J]. 内科理论与实践, 2021, 16(05): 308-314.
[8]	赵英妹, 聂红明, 张珏, 黄燕. 肝硬化患者凝血五项的测定及其临床意义[J]. 诊断学理论与实践, 2021, 20(05): 480-483.
[9]	李涛, 陈皓. 肝硬化门静脉高压症的肝移植治疗[J]. 外科理论与实践, 2021, 26(03): 189-194.
[10]	罗蒙, 李泓杰, 郑磊. 肝硬化门静脉高压症发病机制的研究现状[J]. 外科理论与实践, 2021, 26(03): 195-198.
[11]	胡明礼, 王绮夏, 马雄. 肝硬化食管胃底静脉曲张的药物治疗[J]. 外科理论与实践, 2021, 26(03): 203-207.
[12]	陈炜, 卜俊峰. 肝功能评估方式及在门静脉高压症围术期的应用[J]. 外科理论与实践, 2021, 26(03): 212-216.
[13]	吴城孝, 方婕, 周霁川, 肖永胜, 张晓光. 基于TCGA数据库肝细胞癌microRNA-324-5p表达与预后危险因素分析[J]. 外科理论与实践, 2021, 26(03): 249-253.
[14]	李少博, 杨迪, 韩峻峰. 身体成分变化与非酒精性脂肪性肝病的相关研究进展[J]. 诊断学理论与实践, 2021, 20(01): 104-108.
[15]	王丽娟, 潘自来, 苏文婷, 徐敬慈, 饶敏, 刘宵. 非对比剂增强磁共振血管成像流入反转恢复序列在肝硬化门静脉高压患者门静脉系统成像的可行性研究[J]. 诊断学理论与实践, 2020, 19(05): 494-498.